ARM vs Qualcomm: growth premium against valuation cushion

As of Oct. 30, 2026, ARM was down 11.60% to $202.23 and QCOM was down 11.71% to $163.69. ARM’s 25.1% latest revenue growth contrasts with a 234.0x P/E, 0.6% FCF yield and model-implied 18.2% downside; QCOM’s latest revenue growth was 1.9%, but its 17.3x forward P/E, 5.3% FCF yield and model-implied 23.1% upside support a more favorable risk-adjusted profile, according to the article. Both report after hours on Nov. 4, 2026; consensus EPS and revenue are $0.41 and $1.07B for ARM, and $2.17 and $10.14B for QCOM.

Analysis

The selloff creates a relative-value question, not evidence that the two businesses face the same earnings shock. ARM’s valuation makes it unusually sensitive to any deceleration in licensing or royalty growth: even a solid print could disappoint if forward expectations do not move higher. QCOM’s cheaper cash-flow profile may cushion multiple compression, but that cushion is not a catalyst if handset demand and estimate revisions keep deteriorating. The model-derived fair values and older ARM analyst target are not independent proof of mispricing; treat their disagreement as a signal to focus on guidance and estimate changes, not as a price target.

Near term, both Nov. 4 after-hours reports raise event risk, and the recent price declines may reflect expectations being reset ahead of results. Over 1–3 months, the key distinction is whether ARM converts growth into durable forward estimates and whether QCOM stabilizes estimates. Over 6–18 months, monitor whether ARM’s architecture position translates into recurring monetization without customer substitution, and whether QCOM can reduce reliance on a weak handset cycle through other businesses; the supplied data do not establish either outcome. The contrarian angle is that QCOM’s apparent valuation cushion could be a value trap if estimates continue to fall, while ARM’s premium could persist if guidance sustains exceptional growth. A relative position is therefore preferable to an unhedged directional call, but should wait for the earnings gap risk to clear.

Key Decisions for Investors

• Consider a modest, staged QCOM-versus-ARM pair only after Nov. 4 results: long QCOM, short ARM, sized for relative rather than market-direction exposure. The thesis is valuation resilience versus expectation risk, not that QCOM is immune to estimate cuts. Avoid entering at full size before both reports.
• For ARM, require evidence in forward revenue/royalty guidance and subsequent estimate revisions before adding exposure; a headline EPS beat without stronger forward expectations would not invalidate the valuation-risk thesis. Falsifier: sustained upward revisions accompanied by guidance that supports continued exceptional growth.
• For QCOM, track handset-related outlook and whether EPS/revenue revisions stop worsening. Falsifier for the long leg: further guidance deterioration or continued downward revisions that overwhelm the low-multiple/FCF support.
• Reassess the pair if post-earnings relative performance and estimate trends diverge from the thesis; the key missing checks are the companies’ detailed segment outlooks and the market’s post-print revision response. No standalone options trade is warranted from the supplied information.